Related Articles
The ESMO Manifesto: Outlining Key Areas to Unleash the Potential of the EU Beating Cancer Plan
An evidence-based and patient-centred approach to close the care gap for a healthier Europe
ESMO Gynaecological Cancers Congress 2024: Abstracts
The abstract submission will open soon
ESMO Gastrointestinal Cancers Congress 2024: Abstracts
Abstract submission is now open!
Lymphomas: Essentials for Clinicians
The aim of this web section is to transform learning on lymphomas into an easy and enjoyable experience by using a very visual and didactic…
The ESMO Manifesto: Outlining Key Areas to Unleash the Potential of the EU Beating Cancer Plan
An evidence-based and patient-centred approach to close the care gap for a healthier Europe
ESMO Pocket Guidelines & Mobile App
ESMO’s mobile app: “ESMO Cancer Guidelines” features six titles each one providing the essential recommendations on a specific topic.
Are ADCs in lung cancer living up to expectations?
High rates of adverse events in the experimental setting seem to limit the potential of antibody–drug conjugates for patients with NSCLC
Incorporating ctDNA into clinical trial design
ctDNA offers immense possibilities for improving the management of early-stage lung cancer
How can proteomics aid the study of lung cancer in never smokers?
Personalised proteogenomics has the power to transform the identification, staging and management of NSCLC in never smokers
Post-progression data confirm benefits of novel combos NSCLC
Analyses of FLAURA2, MARIPOSA, MARIPOSA-2 trials provide further guidance on treatments for advanced lung cancer, questions remain about sequencing